Research has recently confirmed that Ozempic, a diabetes medication, may also reduce alcohol consumption. In a small clinical trial involving 48 participants with moderate alcohol-use disorder, individuals administered low doses of semaglutide (the active ingredient in Ozempic) for nine weeks reported noticeably decreased alcohol intake and cravings compared to those receiving a placebo. This study aligns with previous observations suggesting these GLP-1 receptor agonists can diminish the appetite for both food and alcohol.
Lead researcher Christian Hendershot noted the significant reductions in drinking were unexpected and promised further exploration into how these medications may provide new treatment pathways for alcohol-use disorder (AUD), which affects nearly 30 million Americans. Although past therapies for AUD exist, fewer than 2% of affected individuals seek treatment due to various barriers, including stigma and lack of awareness.
The trial showcased that while semaglutide reduced the amount consumed by users, it did not impact the frequency of drinking days. As scientists continue to investigate this potential benefit, the results may pave the way for GLP-1 medications to be integrated into AUD treatment plans, alongside their established roles in diabetes and weight management. Further, ongoing studies aim to understand the implications of using these drugs for other dependencies, including smoking.